American Medical Systems (AMS), an Endo Health Solutions company, and Allergan have entered into an agreement to jointly develop and seek regulatory approval for the delivery of Botox (onabotulinumtoxinA) using the JetTouch system.
AMS’ JetTouch has the potential to enable needle-free injection into any area of the body reachable by endoscopic or percutaneous access.
Under the co-development agreement, AMS will first develop JetTouch for general use in the bladder.
Botox is currently under the US Food and Drug Administration (FDA) review as a potential treatment for overactive bladder with symptoms of urinary incontinence, urgency and frequency in adult patients, who are intolerant of an anticholinergic medication.
Endo Health Solutions chief scientific officer and R&D executive vice president Ivan Gergel said, "With AMS’ position in the urology marketplace, the potential of the JetTouch system combined with the delivery of BOTOX make this a mutually beneficial business opportunity."
In August 2011, Botox was approved by the FDA for the treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition in adults, who are intolerant of an anticholinergic medication.